

RICHARD J. GREGORY et al.
Application No.: 08/328,673
Page 2

PATENT

-- 33. The adenovirus vector of claim 32, wherein the tumor suppressor gene is p53. --

-- 34. The adenovirus vector of claim 32, wherein the tumor suppressor gene is retinoblastoma. --

-- 35. The adenovirus vector of claim 32, wherein the adenovirus is replication deficient. --

-- 36. The adenovirus vector of claim 35, wherein an essential gene for adenovirus replication is deleted.--

-- 37. The adenovirus vector of claim 36, wherein the essential gene is E1A, E1B, or E1A and E1B. --

REMARKS

Applicants thank Examiner Weiss for the helpful telephone conference of October 11, 1996, regarding this application. The following amendments and remarks are submitted further to that conversation.

Applicants have added new claims 32-37. These claims are consistent with the restriction requirement imposed in the Office Action mailed April 16, 1996. Applicants note that support for these new claims can be found throughout the specification, especially as follows. Claims 32-34: p. 5, lines 28-32; claims 35-37: p. 13, lines 20-35.

Applicants respectfully submit that an interference may be appropriate between Applicants' above-identified patent application, U.S. Patent Application No. 08/328,673 (hereinafter referred to as the "Gregory application") and one or more co-pending third-party applications listing Wei-Wei Zhang and/or Jack A. Roth as inventors and claiming priority from or having U.S. Patent Application No. 08/145,826 (hereinafter referred to as the "Roth application(s)"), and applications listing Michel Perricaudet and/or Hedi Haddada and/or Evelyn May claiming priority from FR 93/04745 (hereinafter referred to as the